Risk factors

Verastem carries heavy financial risk with $955.5 million in accumulated deficit, a new $150.0 million debt facility, and required going concern evaluations. The company faces high regulatory hurdles for clinical trials and commercialization of its lead oncology candidates, avutometinib and defactinib. Reliance on third-party manufacturers, clinical investigators, and licensing partners like Pfizer and Chugai exposes the pipeline to external failures.

vTv Therapeutics is entirely dependent on securing additional capital to fund its operations and clinical trials. The company focuses heavily on developing its lead drug candidate, cadisegliatin (TTP399), for type 1 diabetes. Intellectual property protection and third-party dependencies like CROs and manufacturers dominate the operational risks.

Westwater Resources faces going concern doubts following significant historical losses since uranium production ceased in 2009.

Substantial doubt exists regarding our ability to continue as a going concern due to recurring losses and negative cash flows.

Mortgage origination depends heavily on loan production, secondary-market sales, and Fannie Mae and Freddie Mac.

YUTREPIA approval and United Therapeutics patent litigation dominate near-term commercial risk.

Alumis is a clinical-stage biopharmaceutical company focused on immunology, dominated by merger risks with Acelyrin and pipeline execution.

Best Buy relies heavily on five major suppliers representing 55% of merchandise purchases. The company faces significant fourth-quarter holiday sales concentration and supply chain vulnerabilities. Expanding health technology and marketplace platforms introduce complex regulatory and operational risks.

The company's risks are dominated by real estate loan concentration, interest rate sensitivity, and credit loss exposures. Goodwill impairments and cybersecurity threats present additional significant financial and operational exposures.

Customer concentration is high, with one customer representing 29.5% of total revenues in 2024. Operations depend heavily on specialized manufacturing facilities in Central Islip and Saugerties, New York. Geopolitical tensions and supply chain constraints create ongoing risks for procuring raw materials like nickel and integrated circuits.

Damora Therapeutics transitioned to oncology and liver diseases with GB3226 and GB1211 following the October 2024 Bridge Medicines transaction. The company faces a going concern warning, net losses of $21.4 million in 2024, and severe capital constraints with a public float of only $7.3 million.

Fluctuating oil and natural gas prices heavily impact revenues, liquidity, and ability to access capital. Operations are geographically concentrated in Pennsylvania and Texas, exposing the business to regional and pipeline capacity risks. Third-party operators run approximately 99% of oil and natural gas properties, limiting direct operational control.